Insurance

Medicaid Coverage for GLP-1: State-by-State Overview

GLP-1 Companion · 9 min read

Medicaid, the joint federal-state health insurance program for low-income individuals and families, is administered differently in every state. This means GLP-1 coverage under Medicaid varies more widely than under any other insurance type — from states that cover weight-management GLP-1s with standard prior authorization, to states that restrict access entirely to type 2 diabetes indications, to states that require multiple prior treatment failures before approving any anti-obesity medication. Understanding your state's rules is the essential first step.

Why Coverage Varies So Much by State

Federal Medicaid law establishes minimum coverage requirements but gives states broad discretion to set their own formularies (preferred drug lists), prior authorization criteria, and coverage exclusions. States pay a portion of Medicaid costs themselves, so they have a direct financial incentive to limit coverage of high-cost medications like GLP-1 drugs. The result is a highly variable landscape where geography significantly determines whether a low-income patient can access these medications through their insurance.

Type 2 Diabetes Coverage: More Universal

Across states, GLP-1 medications prescribed for the management of type 2 diabetes — including Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Victoza and Trulicity (liraglutide and dulaglutide) — are more broadly covered than those prescribed for obesity alone. This is because diabetes management is an essential benefit under Medicaid, and GLP-1 medications have strong evidence for glycemic control. Even states with limited obesity drug coverage typically cover at least one GLP-1 for T2D, though prior authorization criteria may be strict and step therapy may be required (e.g., metformin before GLP-1 approval).

Weight Management Coverage: Highly Variable

Coverage of GLP-1 medications specifically for chronic weight management — meaning Wegovy, Zepbound, or Saxenda prescribed for obesity rather than diabetes — is where state variation is most pronounced. A growing number of states have moved to cover these medications, driven by evidence of long-term health cost savings, but many have not.

States with Broader GLP-1 Obesity Coverage

Several states have adopted policies covering anti-obesity medications including GLP-1s for qualifying Medicaid beneficiaries.

• California: California Medicaid (Medi-Cal) added coverage for FDA-approved anti-obesity medications including Wegovy and Zepbound in 2024, with standard prior authorization criteria (BMI ≥30 or ≥27 with comorbidity)
• New York: New York Medicaid covers anti-obesity pharmacotherapy with prior authorization; GLP-1s are included for qualifying beneficiaries meeting BMI and comorbidity criteria
• Oregon: Oregon Health Plan expanded obesity drug coverage as part of its 2024 benefit updates; prior authorization required with step therapy in some cases
• Colorado: added GLP-1 obesity coverage as part of a broader anti-obesity benefit expansion
• Washington: covers some anti-obesity medications under its Medicaid program with PA criteria

States with Limited or No Obesity GLP-1 Coverage

Many states have not yet added weight-management GLP-1 coverage to their Medicaid formularies, restricting access to the diabetes indication only or excluding anti-obesity medications altogether. As of early 2026, states in this category include many Southern and Midwestern states. However, this landscape is changing; check your state's current PDL rather than relying on dated information.

How to Check Your State's Preferred Drug List

Your state's Medicaid Preferred Drug List (PDL) is the authoritative source of information about which GLP-1 medications are covered, what tier they are on, and what prior authorization criteria apply. Here is how to find it.

1. Search "[your state] Medicaid Preferred Drug List" or "[your state] Medicaid PDL" — most states publish their PDL online and update it quarterly
2. Look for the therapeutic category "GLP-1 receptor agonists," "incretin mimetics," or "anti-obesity agents" depending on how your state categorizes these drugs
3. Note whether each GLP-1 is listed as preferred (PA may be simpler) or non-preferred (PA criteria are typically stricter and may require step therapy through a preferred alternative first)
4. Check the PA criteria document, which is usually linked from the PDL and specifies exact BMI thresholds, required comorbidities, and step therapy requirements
5. Call your state Medicaid office directly or your managed care plan's pharmacy help line if you cannot locate the information online

Medicaid Managed Care vs. Fee-for-Service

Most Medicaid beneficiaries are enrolled in Medicaid managed care organizations (MCOs) — private health plans that contract with the state to provide Medicaid benefits. MCOs may have their own formularies and PA criteria that differ from the state's base PDL, sometimes more restrictive and sometimes more permissive. If you are in a Medicaid MCO, check your specific plan's formulary rather than the state's base PDL. If your MCO does not cover a GLP-1 that the state's fee-for-service program would cover, you may be able to request a formulary exception.

Prior Authorization Under Medicaid

When Medicaid does cover a GLP-1 medication, prior authorization is almost always required. Medicaid PA criteria are often stricter than commercial insurance criteria and may include.

• Higher BMI thresholds than commercial insurance (some state Medicaid programs require BMI ≥35 rather than ≥30)
• Documented failure of structured behavioral weight-loss interventions for 6 months or longer
• Step therapy requirements mandating trial of an older, less expensive agent (orlistat, phentermine, bupropion/naltrexone) before a GLP-1 is approved
• More limited initial authorization periods (3 to 6 months in some states, requiring early re-authorization with documented weight loss progress)
• Requirement for prescribing by a specialist (endocrinologist, obesity medicine specialist) rather than a primary care provider

Appealing a Medicaid Denial

Medicaid beneficiaries have the right to appeal any adverse coverage determination. The appeal process for Medicaid has specific timelines and procedures set by both federal law and state rules.

1. Request the written denial notice, which must include the specific reason for the denial and your appeal rights
2. File a "fair hearing" request — this is the standard Medicaid appeal mechanism — within the timeframe specified in your denial notice (typically 30 to 90 days)
3. For expedited appeals when a health condition makes delay unreasonable, request an expedited fair hearing; decisions must be made within 3 business days
4. Gather supporting documentation: clinical notes, BMI records, comorbidity diagnoses, and a prescriber letter of medical necessity
5. Request a prescriber peer-to-peer review with the Medicaid MCO's medical director before or alongside the formal hearing if available
6. If the fair hearing decision is unfavorable, further appeal options may include state court review or federal Medicaid complaint processes

Medicaid Expansion and GLP-1 Access

The ACA Medicaid expansion extended coverage to adults with incomes up to 138% of the federal poverty level in states that chose to expand. As of 2026, 40 states and D.C. have expanded Medicaid. In expansion states, many previously uninsured working-age adults now have Medicaid coverage, which may cover GLP-1 medications if the state's formulary includes them. In the 10 non-expansion states, adults without dependent children often fall into a coverage gap with income too high for traditional Medicaid but too low for ACA marketplace subsidies — leaving them without affordable GLP-1 access.

Income Considerations and Other Assistance

Medicaid coverage is income-based, and your eligibility category may affect which benefits are available. Dual-eligible beneficiaries (enrolled in both Medicaid and Medicare) may have GLP-1 costs covered if they qualify for the Limited Income Subsidy (Extra Help) for Part D, which significantly reduces cost-sharing. For Medicaid beneficiaries whose state does not cover anti-obesity GLP-1s, the manufacturer patient assistance programs (NovoCare, Lilly Cares) may provide an alternative pathway, as these are income-based rather than insurance-based.

Medicaid coverage for GLP-1 anti-obesity medications is expanding, but unevenly. The most effective advocacy is local — engaging your state Medicaid office, your state legislators, and patient advocacy organizations to push for formulary expansion can change outcomes for thousands of low-income patients in your state.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.